Market Overview
Global Market Size
$2.14T
▲ 7.2% CAGR
2026 projected
VC Investment Q1
$18.3B
▲ 34% vs Q4
Biotech + Digital Health
M&A Deals Q1
42
▲ 18% QoQ
Deals >$100M valuation
FDA Approvals YTD
14
▲ 22% vs Q1 '25
Novel molecular entities
IPO Activity
$4.7B
▲ 3 new listings
Total capital raised
Patent Filings
8,420
▲ 11% YoY
US + EP filings
Clinical Pipeline & Innovation
Industry Pipeline by Phase
Active clinical programs across tracked companies, Q1 2026
6,482 Active
1,840
1,260
920
538
312
612
Preclinical
Phase I
Phase II
Phase III
NDA/BLA
Approved
Phase III Pipeline Growth (12mo trailing)
Therapeutic Area Mix
Pipeline distribution by indication
Oncology
28%
Immunology
19%
Neuroscience
15%
Rare Disease
12%
Cell & Gene
8%
Cardiovascular
9%
Metabolic/GLP-1
5%
Infectious Dis.
4%
Funding, M&A & Regulatory Landscape
VC Funding by Stage
Q1 2026 investment breakdown
Total: $18.3B across 214 deals
M&A Activity
Notable deals Q1 2026
| Acquirer | Target | Value | Focus |
|---|---|---|---|
| Pfizer | Oncovax Bio | $8.4B | ADC pipeline |
| Roche | NeuroStar | $5.1B | Neuro AI |
| Amgen | CellForge | $3.8B | Cell therapy |
| Danaher | DiagX | $2.2B | Liquid biopsy |
| J&J | ImmuGen | $1.9B | Autoimmune |
Regulatory Tracker
Key FDA / EMA actions Q1
14 NME approvals — Oncology (5), Rare Disease (3), Neuro (2), Other (4)
Q1
Accelerated Approval overhaul — new confirmatory trial requirements
Feb
AI/ML guidance finalized — Software as Medical Device framework updated
Feb
Biosimilar pathway expanded — 8 new interchangeable designations
Jan
Cell therapy manufacturing — CGMP guidance for autologous therapies
Jan
Geography, Revenue & Innovation
Revenue by Segment — Top 20 Companies
Combined revenue by business unit, trailing 4 quarters
R&D Hubs
By investment volume
Boston / Camb.
28%
SF Bay Area
20%
Basel / Zurich
14%
NJ / Philly
11%
London / Oxford
8%
Shanghai
7%
Other
12%
Innovation Index
Breakthrough signals
8,420
Patent Filings
342
IND Filings YTD
Hottest Modalities
ADCs
+62%
mRNA
+48%
Gene Edit
+41%
Radiopharm
+35%
Market Signals & Competitive Intelligence
Key Market Signals
Industry events shaping the landscape
GLP-1 race intensifies — 4 new Phase III entrants. Eli Lilly, Novo Nordisk, Amgen, and Viking Therapeutics battling for $100B+ market.
Mar
AI drug discovery hits inflection — 3 AI-designed drugs now in Phase II. Recursion, Insilico, Isomorphic Labs leading platform deals >$500M each.
Feb
Cell & Gene manufacturing scale-up — 6 CDMO expansions announced. Samsung Biologics, Lonza, Catalent adding combined 200K sq ft capacity.
Feb
Biosimilar wave accelerates — $48B in branded biologics losing exclusivity 2026-2028. Sandoz, Teva, Samsung Bioepis racing for market share.
Jan
Oncology ADC pipeline explosion — 12 new IND filings in Q1 alone. Daiichi Sankyo, AstraZeneca, Pfizer expanding ADC portfolios aggressively.
Jan
Sub-Sector Performance
Stock index returns, YTD 2026
Market Overview
Total VC Funding Q1
$42.1B
▲ 28% vs Q4
All emerging tech verticals
AI / ML Market
$305B
▲ 38% YoY
2026 projected market
Cyber Market
$212B
▲ 14% YoY
Global cybersecurity spend
IPO / Exits Q1
18
▲ 50% vs Q1 '25
Exits >$500M valuation
Unicorns Created
23
▲ new $1B+ cos in Q1
14 are AI-native
Patent Filings (AI)
14,200
▲ 64% YoY
US + CN + EP filings
Funding Landscape & Sector Maturity
VC Funding by Sector — Quarterly Trend
Investment volume across emerging technology verticals
$142B TTM
Sector Maturity Map
Technology readiness & market phase
Generative AI
Peak Growth
AI Infra / MLOps
Scale-Up
Cybersecurity
Mature
Climate Tech
Growth
Robotics / HW
Growth
Edge / IoT
Growth
Quantum
Early
Spatial / AR-VR
Emerging
Product Adoption & M&A Activity
Enterprise AI Adoption
% of Fortune 500 deploying
GenAI Tools
92%
ML in Prod
74%
Zero Trust
68%
Cloud Native
82%
Edge Deploy
38%
Quantum POC
12%
Major M&A Deals
Notable acquisitions Q1 2026
| Acquirer | Target | Value | Focus |
|---|---|---|---|
| Wiz | $32B | Cloud Security | |
| Salesforce | AgentForce AI | $8.1B | AI Agents |
| Cisco | ShieldNet | $5.4B | Zero Trust |
| NVIDIA | RunPod | $3.2B | GPU Cloud |
| Microsoft | QuantumPath | $2.8B | Quantum SW |
Regulation Tracker
Key policy actions, Q1 2026
EU AI Act enforcement — First compliance deadlines; high-risk AI classification in effect
Feb
NIST post-quantum standards — Mandatory migration timeline for federal contractors
Feb
US AI Executive Order update — Reporting requirements for frontier model developers
Jan
SEC crypto framework — Clear custody rules for digital asset platforms
Jan
Geography, Revenue & Innovation Radar
Cloud & AI Infrastructure Revenue
Quarterly revenue by hyperscaler, trailing 4 quarters
Innovation Hubs
By startup density
SF Bay Area
32%
NYC / NJ
18%
London
13%
Tel Aviv
11%
Seattle
9%
Shenzhen
7%
Other
10%
Innovation Radar
Breakout technology signals
14.2K
AI Patents Filed
1,247
Quantum Patents
Hottest Categories
AI Agents
+340%
AI Safety
+280%
Edge AI
+120%
Humanoid
+95%
Market Signals & Competitive Intelligence
Key Market Signals
Industry events reshaping the technology landscape
AI Agent infrastructure boom — Agentic frameworks driving $4.2B in new funding. Every Series B+ startup adding agent orchestration layers.
Mar
NVIDIA Blackwell Ultra ships — Next-gen GPU architecture reaching hyperscalers. 4x inference throughput vs H100 reshaping economics of AI deployment.
Mar
Post-quantum crypto mandate — NIST standards finalized. Federal contractors have 18-month migration window, driving $8B+ in security spend.
Feb
Humanoid robotics Series B wave — Figure, 1X, Apptronik, Agility raising $100M+ rounds. Manufacturing and logistics deployments accelerating.
Jan
Climate tech IPO window opens — 3 successful listings (carbon capture, battery tech, grid software). Combined market cap $18B on listing day.
Jan
Sub-Sector Performance
Public market returns, YTD 2026